CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated oncology therapeutics, today announced that
the Company presented advances within its conditionally-activated
ADC portfolio, including the next generation EpCAM-ADC, CX-2051, at
the World ADC conference taking place September 6-9, 2022, in San
Diego, CA.
“The momentum in the field of ADC therapeutics
is incredibly exciting and holds great promise for the innovation
and development of novel oncology therapeutics. Our pioneering work
and experience in applying our versatile Probody® platform to the
ADC modality has the potential to expand the universe of
addressable targets and to further increase the therapeutic window
of future molecules entering the clinic,” said Marcia P. Belvin,
Ph.D., senior vice president and head of research at CytomX.
“CX-2051, our EpCAM-targeted, conditionally activated ADC, is
strategically tailored to optimize the therapeutic index for
systemic treatment of EpCAM-expressing epithelial cancers, which is
an area of high unmet need where, to date, efforts have not been
successful due to dose-limiting toxicities.”
“Our strategy with CX-2051 is to match payload
mechanism of action with tumor sensitivity, and we have selected
the topoisomerase-1 inhibitor, camptothecin, as the payload for our
newest ADC,” Dr. Belvin continued. “Topoisomerase-1
inhibitor-conjugated ADCs are showing impressive clinical activity,
and importantly, the safety profiles of camptothecin and its
derivatives have been well characterized. Additionally, two
camptothecin derivatives, irinotecan and topotecan, have been
approved by the U.S. Food and Drug Administration for clinical use
- irinotecan for pancreatic and colorectal cancer, and topotecan
for ovarian, cervical, and small cell lung cancer. We plan to
pursue multiple indications with this new therapeutic candidate and
look forward to progressing to an investigational new drug
application submission in the second half of 2023.”
Presentation highlights
include:
- Review of clinical activity for the
conditionally activated ADCs CX-2029 and praluzatamab ravtansine
(CX-2009), targeting CD71 and CD166, respectively. CD71 and CD166
have historically been inaccessible targets for traditional ADCs
due to their high expression levels on normal tissues. The data
presented demonstrate clinical anti-cancer activity and a
therapeutic window for these previously undruggable targets.
- The molecular structure of CX-2051,
a masked, conditionally activated, EpCAM-targeting ADC with a next
generation camptothecin-based linker payload. CX-2051 highlights
the potential for CytomX’s Probody technology to unlock a new ADC
target (EpCAM/Trop-1), which is a target that has previously
yielded promising clinical results only through locally
administered therapies.
- CX-2051 preclinical data indicating strong anti-cancer activity
and tolerability with a favorable predicted therapeutic index.
The full presentation is available at
the following link:
Tailoring the Selection of Target,
Payload, & Tumor Type to Maximize the Therapeutic Index of
Conditionally Activated ADCs Marcia P. Belvin, Ph.D.,
Senior Vice President, Head of Research, CytomX
TherapeuticsPresentation Link
About CytomX Therapeutics,
Inc.CytomX is a clinical-stage, oncology-focused
biopharmaceutical company dedicated to destroying cancer
differently. By pioneering a novel class of conditionally activated
biologics, powered by its Probody® technology platform, CytomX’s
goal is to transcend the limits of current cancer treatments.
CytomX’s robust and differentiated pipeline comprises seven
therapeutic candidates across multiple treatment modalities. Three
of these candidates are in Phase 2 studies across multiple cancer
types, including CX-2029 and praluzatamab ravtansine. CX-2029 is an
investigational conditionally activated antibody-drug conjugate
(ADC) directed toward CD71, which has demonstrated encouraging
antitumor activity in patients with squamous non-small cell lung
cancer and is being developed in collaboration with AbbVie.
Praluzatamab ravtansine is an investigational conditionally
activated ADC directed toward CD166 and is being studied in
patients with advanced breast cancer. CytomX’s clinical pipeline
also includes cancer immunotherapeutic candidates against validated
targets such as the CTLA-4-targeting Probody therapeutics,
BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, as
well as CX-904, a conditionally activated T-cell-engaging
bispecific antibody targeting the epidermal growth factor receptor
on tumor cells and the CD3 receptor on T cells, which is partnered
with Amgen. In addition, CytomX has a diverse preclinical portfolio
of wholly-owned assets such as CX-801, an interferon alpha-2b
Probody cytokine that has broad potential applicability in
traditionally immuno-oncology sensitive as well as insensitive
(cold) tumors and CX-2051, a conditionally activated ADC directed
toward EpCAM, with potential applicability across multiple
EpCAM-expressing epithelial cancers. CytomX has established
strategic collaborations with multiple leaders in oncology,
including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For
more information about CytomX and how it is working to make
conditionally activated treatments the new standard-of-care in the
fight against cancer, visit www.cytomx.com and follow us on
LinkedIn and Twitter.
Forward-Looking StatementsThis
press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements, including those related to the
potential of Antibody Drug Conjugates, Probody Drug Conjugates or
CX-2051. Accordingly, you should not rely on any of these
forward-looking statements, including those relating to the
potential benefits, safety and efficacy or progress of CytomX’s or
any of its collaborative partners’ product candidates, including
praluzatamab ravtansine, CX-2029, BMS-986249, BMS-986288,
pacmilimab, CX-904, CX-801, and CX-2051, the potential benefits or
applications of CytomX’s Probody platform technology, CytomX’s
ability to develop and advance product candidates into and
successfully complete clinical trials, including the ongoing and
planned clinical trials of praluzatamab ravtansine, CX-2029,
BMS-986249, BMS-986288, pacmilimab, and CX-904, and the timing of
the commencement of clinical trials, initial and ongoing data
availability, investigational new drug applications and other
development milestones. Risks and uncertainties that contribute to
the uncertain nature of the forward-looking statements include: the
unproven nature of CytomX’s novel Probody Platform technology;
CytomX’s clinical trial product candidates are in the initial
stages of clinical development and its other product candidates are
currently in preclinical development, and the process by which
preclinical and clinical development could potentially lead to an
approved product is long and subject to significant risks and
uncertainties, including the risk that the COVID-19 worldwide
pandemic may continue to negatively impact the business, research
and clinical operations of CytomX or its partners, including the
development of preclinical drug candidates due to delays in and
disruption of research activities and the development of clinical
drug candidates due to delays in or disruption of clinical trials,
including impacts on the enrollment of patients in clinical trials
or other clinical trial disruptions; the possibility that the
results of preclinical research and early clinical trials may not
be predictive of future results; the possibility that CytomX’s
clinical trials will not be successful; the possibility that
current preclinical research may not result in additional product
candidates; CytomX’s dependence on the success of praluzatamab
ravtansine, CX-2029, BMS-986249, BMS-986288, pacmilimab, CX-904,
CX-801, and CX-2051; CytomX’s reliance on third parties for the
manufacture of the Company’s product candidates; and possible
regulatory developments in the United States and foreign
countries. Additional applicable risks and uncertainties include
those relating to our preclinical research and development,
clinical development, and other risks identified under the heading
"Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q
filed with the SEC on August 4, 2022. The
forward-looking statements contained in this press release are
based on information currently available to CytomX and speak only
as of the date on which they are made. CytomX does not undertake
and specifically disclaims any obligation to update any
forward-looking statements, whether as a result of any new
information, future events, changed circumstances or otherwise.
Probody is a U.S. registered trademark of CytomX
Therapeutics, Inc.
CytomX Contact:Chris
OgdenSenior Vice President, Head of Financecogden@cytomx.com(317)
767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com(212) 362-1200
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024